Pharmacological targets revealed by myocardial postconditioning

Current Opinion in Pharmacology

Volumn 9, Issue 2, 2009, Pages 177-188

  Burley, Dwaine S ^a   Baxter, Gary F ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 4 [7 [[1 [(3 CHLORO 2 THIENYL)METHYL]PROPYL]AMINO] 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] N ETHYL 2,3 DIHYDROXYCYCLOPENTANECARBOXAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; [[4 [2 [[BIS(CYCLOHEXYLAMINO)METHYLENE]AMINO] 3 (2 NAPHTHYL)PROPIONAMIDO]PHENYL]METHYL]TRIBUTYLPHOSPHONIUM CHLORIDE; ADENOSINE; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; ADRENOMEDULLIN; ANESTHETIC AGENT; ATRIAL NATRIURETIC FACTOR; AUTACOID; BRADYKININ; FENTANYL ISOTHIOCYANATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICATIBANT; ISATIN; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; NALOXONE; NALTRINDOLE; NICORANDIL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NITRATE; NORBINALTORPHIMINE; OPIATE PEPTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; UNINDEXED DRUG;

ACUTE HEART INFARCTION; APOPTOSIS; CARDIOGENIC SHOCK; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEATH; DISEASE MODEL; DRUG TARGETING; ENZYME ACTIVATION; FIBRINOLYSIS; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HUMAN; ISCHEMIC POSTCONDITIONING; MITOCHONDRIAL PERMEABILITY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; ST SEGMENT ELEVATION; STROKE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; ATRIAL NATRIURETIC FACTOR; AUTACOIDS; CARDIOTONIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; RECEPTORS, OPIOID; RECEPTORS, PURINERGIC P1;

EID: 62249175465     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.11.009     Document Type: Review

References (131)

1. Ferdinandy P., Schulz R., and Baxter G.F. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 59 (2007) 418-458. Comprehensive review of the relationships between different risk factors of heart disease and ischaemia-reperfusion.
2. Yellon D.M., and Hausenloy D.J. Myocardial reperfusion injury. N Engl J Med 357 (2007) 1121-1135. Comprehensive review assessing mechanisms of reperfusion injury and providing clinical context.
3. Dirksen M.T., Laarman G.J., Simoons M.L., and Duncker D.J. Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc Res 74 (2007) 343-355. State-of-the-art review of the evidence for myocardial reperfusion injury in humans, together with a summary of major clinical trials of pharmacological adjuncts to reperfusion in AMI.
4. Penna C., Mancardi D., Raimondo S., Geuna S., and Pagliaro P. The paradigm of postconditioning to protect the heart. J Cell Mol Med 12 (2008) 435-458
5. Zhao Z.Q., Corvera J.S., Halkos M.E., Kerendi F., Wang N.P., Guyton R.A., and Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285 (2003) H579-588
6. Na H.S., Kim Y.I., Yoon Y.W., Han H.C., Nahm S.H., and Hong S.K. Ventricular premature beat-driven intermittent restoration of coronary blood flow reduces the incidence of reperfusion-induced ventricular fibrillation in a cat model of regional ischemia. Am Heart J 132 (1996) 78-83
7. Staat P., Rioufol G., Piot C., Cottin Y., Cung T.T., L'Huillier I., Aupetit J.F., Bonnefoy E., Finet G., Andre-Fouet X., et al. Postconditioning the human heart. Circulation 112 (2005) 2143-2148
8. Thibault H., Piot C., Staat P., Bontemps L., Sportouch C., Rioufol G., Cung T.T., Bonnefoy E., Angoulvant D., Aupetit J.F., et al. Long-term benefit of postconditioning. Circulation 117 (2008) 1037-1044. Evidence that postconditioning affords persistent infarct size limitation in human myocardium six months after acute myocardial infarction. This paper is a follow-up on reference [6] that documented the first evidence in human patients of the effectiveness of ischaemic postconditioning.
9. Kin H., Zatta A.J., Lofye M.T., Amerson B.S., Halkos M.E., Kerendi F., Zhao Z.Q., Guyton R.A., Headrick J.P., and Vinten-Johansen J. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res 67 (2005) 124-133
10. ATP channels in both normal and hypercholesterolemic rabbits. J Cardiovasc Pharmacol 49 (2007) 287-292
11. 2b receptor cascade. Cardiovasc Res 70 (2006) 308-314
12. Yang X.M., Philipp S., Downey J.M., and Cohen M.V. Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol 100 (2005) 57-63
13. 2A adenosine receptors attenuates the protective effects of myocardial postconditioning. Am J Physiol Heart Circ Physiol 293 (2007) H2523-2529
14. Olafsson B., Forman M.B., Puett D.W., Pou A., Cates C.U., Friesinger G.C., and Virmani R. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation 76 (1987) 1135-1145
15. 1 agonist at reperfusion trial (AART): results of a three-center, blinded, randomized, controlled experimental infarct study. Cardiovasc Drugs Ther 14 (2000) 607-614
16. Goto M., Miura T., Iliodoromitis E.K., O'Leary E.L., Ishimoto R., Yellon D.M., and Iimura O. Adenosine infusion during early reperfusion failed to limit myocardial infarct size in a collateral deficient species. Cardiovasc Res 25 (1991) 943-949
17. Homeister J.W., Hoff P.T., Fletcher D.D., and Lucchesi B.R. Combined adenosine and lidocaine administration limits myocardial reperfusion injury. Circulation 82 (1990) 595-608
18. 1-receptor agonist, in myocardial ischaemia-reperfusion injury in the pig. J Cardiovasc Pharmacol 33 (1999) 285-291
19. 2-receptor agonists on myocardial reperfusion injury. Am Heart J 123 (1992) 332-338
20. Pitarys II C.J., Virmani R., Vildibill Jr. H.D., Jackson E.K., and Forman M.B. Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period. Circulation 83 (1991) 237-247
21. 1-selective adenosine analogues protects the heart against infarction. Circulation 85 (1992) 659-665
22. Vander Heide R.S., and Reimer K.A. Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs. Cardiovasc Res 31 (1996) 711-718
23. Velasco C.E., Turner M., Cobb M.A., Virmani R., and Forman M.B. Myocardial reperfusion injury in the canine model after 40 min of ischemia: effect of intracoronary adenosine. Am Heart J 122 (1991) 1561-1570
24. 1 receptor mediated myocardial infarct size reduction by endogenous adenosine is exerted primarily during ischaemia. Cardiovasc Res 28 (1994) 270-279
25. 2A receptor and ERK1/2. Cardiovasc Drugs Ther 17 (2003) 415-425
26. 2-receptor agonist AMP, 579: coronary hemodynamic and cardioprotective effects in the canine myocardium. J Cardiovasc Pharmacol 33 (1999) 703-710
27. 2 receptor agonist AMP 579 in a porcine model of myocardial infarction. J Pharmacol Exp Ther 286 (1998) 611-618
28. Xu Z., Downey J.M., and Cohen M.V. Timing and duration of administration are crucial for anti-infarct effect of AMP 579 infused at reperfusion in rabbit heart. Heart Dis 5 (2003) 368-371
29. Xu Z., Yang X.M., Cohen M.V., Neumann T., Heusch G., and Downey J.M. Limitation of infarct size in rabbit hearts by the novel adenosine receptor agonist AMP 579 administered at reperfusion. J Mol Cell Cardiol 32 (2000) 2339-2347
30. Forster K., Paul I., Solenkova N., Staudt A., Cohen M.V., Downey J.M., Felix S.B., and Krieg T. NECA at reperfusion limits infarction and inhibits formation of the mitochondrial permeability transition pore by activating p70S6 kinase. Basic Res Cardiol 101 (2006) 319-326
31. Yang X.M., Krieg T., Cui L., Downey J.M., and Cohen M.V. NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK, and NO. J Mol Cell Cardiol 36 (2004) 411-421
32. 2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation. Am J Physiol Heart Circ Physiol 295 (2008) H1825-H1833
33. 2B receptor antagonist ZM-241385 blocks the cardioprotective effect of adenosine agonist pretreatment in in vivo rat myocardium. Am J Physiol Heart Circ Physiol 292 (2007) H426-431
34. 2B agonists by protein kinase C. Am J Physiol Heart Circ Physiol 295 (2008) H1288-H1295
35. 2A agonists in a canine model of myocardial stunning produced by multiple episodes of transient ischemia. Am J Physiol Heart Circ Physiol 292 (2007) H3164-3171
36. 3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs. Am J Physiol Heart Circ Physiol 285 (2003) H607-613
37. 3 adenosine receptor. J Pharmacol Exp Ther 319 (2006) 1200-1210
38. 1 adenosine receptor. Basic Res Cardiol 96 (2001) 487-496
39. 3 receptor agonist, IB-MECA. Eur J Pharmacol 477 (2003) 235-245
40. 3 receptor activation protects the myocardium from reperfusion/reoxygenation injury. Am J Physiol Heart Circ Physiol 283 (2002) H1307-1313
41. Park S.S., Zhao H., Jang Y., Mueller R.A., and Xu Z. N6-(3-iodobenzyl)-adenosine-5'-N-methylcarboxamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase 3 beta. J Pharmacol Exp Ther 318 (2006) 124-131
42. Mahaffey K.W., Puma J.A., Barbagelata N.A., DiCarli M.F., Leesar M.A., Browne K.F., Eisenberg P.R., Bolli R., Casas A.C., Molina-Viamonte V., et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 34 (1999) 1711-1720
43. Kopecky S.L., Aviles R.J., Bell M.R., Lobl J.K., Tipping D., Frommell G., Ramsey K., Holland A.E., Midei M., Jain A., et al. A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am Heart J 146 (2003) 146-152
44. Ross A.M., Gibbons R.J., Stone G.W., Kloner R.A., and Alexander R.W. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 45 (2005) 1775-1780
45. Cohen M.V., and Downey J.M. AMISTAD trials: possible reasons for lack of success. J Am Coll Cardiol 47 (2006) 1236 author reply 1236-1237
46. Jang Y., Xi J., Wang H., Mueller R.A., Norfleet E.A., and Xu Z. Postconditioning prevents reperfusion injury by activating delta-opioid receptors. Anesthesiology 108 (2008) 243-250
47. Zatta A.J., Kin H., Yoshishige D., Jiang R., Wang N., Reeves J.G., Mykytenko J., Guyton R.A., Zhao Z.Q., Caffrey J.L., et al. Evidence that cardioprotection by postconditioning involves preservation of myocardial opioid content and selective opioid receptor activation. Am J Physiol Heart Circ Physiol 294 (2008) H1444-1451
48. Gross E.R., Hsu A.K., and Gross G.J. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ Res 94 (2004) 960-966
49. Gross E.R., Peart J.N., Hsu A.K., Auchampach J.A., and Gross G.J. Extending the cardioprotective window using a novel delta-opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway. Am J Physiol Heart Circ Physiol 288 (2005) H2744-2749
50. Peart J.N., Gross E.R., Reichelt M.E., Hsu A., Headrick J.P., and Gross G.J. Activation of kappa-opioid receptors at reperfusion affords cardioprotection in both rat and mouse hearts. Basic Res Cardiol 103 (2008) 454-463
51. Weihrauch D., Krolikowski J.G., Bienengraeber M., Kersten J.R., Warltier D.C., and Pagel P.S. Morphine enhances isoflurane-induced postconditioning against myocardial infarction: the role of phosphatidylinositol-3-kinase and opioid receptors in rabbits. Anesth Analg 101 (2005) 942-949 table of contents
52. Chen Z., Li T., and Zhang B. Morphine postconditioning protects against reperfusion injury in the isolated rat hearts. J Surg Res 145 (2008) 287-294
53. Bell R.M., and Yellon D.M. Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K. Akt and eNOS. J Mol Cell Cardiol 35 (2003) 185-193
54. ATP channels trigger cardiac postconditioning through redox signaling. Cardiovasc Res 75 (2007) 168-177
55. Penna C., Mancardi D., Tullio F., and Pagliaro P. Postconditioning and intermittent bradykinin induced cardioprotection require cyclooxygenase activation and prostacyclin release during reperfusion. Basic Res Cardiol 103 (2008) 368-377
56. Hamid S.A., and Baxter G.F. Adrenomedullin limits reperfusion injury in experimental myocardial infarction. Basic Res Cardiol 100 (2005) 387-396
57. Schulman D., Latchman D.S., and Yellon D.M. Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. Am J Physiol Heart Circ Physiol 283 (2002) H1481-1488
58. Baxter G.F. Natriuretic peptides and myocardial ischaemia. Basic Res Cardiol 99 (2004) 90-93
59. Burley D.S., and Baxter G.F. B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heart. Basic Res Cardiol 102 (2007) 529-541
60. Inserte J., Garcia-Dorado D., Agullo L., Paniagua A., and Soler-Soler J. Urodilatin limits acute reperfusion injury in the isolated rat heart. Cardiovasc Res 45 (2000) 351-359
61. Padilla F., Garcia-Dorado D., Agullo L., Barrabes J.A., Inserte J., Escalona N., Meyer M., Mirabet M., Pina P., and Soler-Soler J. Intravenous administration of the natriuretic peptide urodilatin at low doses during coronary reperfusion limits infarct size in anesthetized pigs. Cardiovasc Res 51 (2001) 592-600
62. ATP channel activation.
63. Kitakaze M., Asakura M., Kim J., Shintani Y., Asanuma H., Hamasaki T., Seguchi O., Myoishi M., Minamino T., Ohara T., et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 370 (2007) 1483-1493. Demonstration of infarct-limiting effect of recombinant human ANP, but not nicorandil, given as an adjunct to PCI in patients presenting with ST-elevation AMI. The study is of particular interest in providing lessons for the design of future trials of this type.
64. Yellon D.M., and Baxter G.F. Reperfusion injury revisited: is there a role for growth factor signaling in limiting lethal reperfusion injury?. Trends Cardiovasc Med 9 (1999) 245-249
65. Tsang A., Hausenloy D.J., Mocanu M.M., and Yellon D.M. Postconditioning: a form of 'modified reperfusion' protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 95 (2004) 230-232
66. Bullard A.J., Govewalla P., and Yellon D.M. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 100 (2005) 397-403
67. Bell R.M., and Yellon D.M. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 41 (2003) 508-515
68. Efthymiou C.A., Mocanu M.M., and Yellon D.M. Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling. J Cardiovasc Pharmacol 45 (2005) 247-252
69. Wolfrum S., Dendorfer A., Schutt M., Weidtmann B., Heep A., Tempel K., Klein H.H., Dominiak P., and Richardt G. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 44 (2004) 348-355
70. Chiari P.C., Bienengraeber M.W., Pagel P.S., Krolikowski J.G., Kersten J.R., and Warltier D.C. Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: evidence for anesthetic-induced postconditioning in rabbits. Anesthesiology 102 (2005) 102-109
71. Lim S.Y., Davidson S.M., Paramanathan A.J., Smith C.C., Yellon D.M., and Hausenloy D.J. The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med 12 (2008) 1395-1403
72. Smith C.C., Mocanu M.M., Davidson S.M., Wynne A.M., Simpkin J.C., and Yellon D.M. Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects. Br J Pharmacol 149 (2006) 5-13
73. Bhamra G.S., Hausenloy D.J., Davidson S.M., Carr R.D., Paiva M., Wynne A.M., Mocanu M.M., and Yellon D.M. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol 103 (2008) 274-284
74. Jiang R., Zatta A., Kin H., Wang N., Reeves J.G., Mykytenko J., Deneve J., Zhao Z.Q., Guyton R.A., and Vinten-Johansen J. PAR-2 activation at the time of reperfusion salvages myocardium via an ERK1/2 pathway in in vivo rat hearts. Am J Physiol Heart Circ Physiol 293 (2007) H2845-2852
75. Hausenloy D.J., Tsang A., and Yellon D.M. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 15 (2005) 69-75
76. Solenkova N.V., Solodushko V., Cohen M.V., and Downey J.M. Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt. Am J Physiol Heart Circ Physiol 290 (2006) H441-449
77. Hausenloy D.J., and Yellon D.M. Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther 116 (2007) 173-191
78. Burley D.S., and Baxter G.F. Activation of particulate guanylate cyclase during early reperfusion limits infarct size in the rat isolated heart. J Mol Cell Cardiol 42 (2007) S209
79. Abdallah Y., Gkatzoflia A., Pieper H., Zoga E., Walther S., Kasseckert S., Schafer M., Schluter K.D., Piper H.M., and Schafer C. Mechanism of cGMP-mediated protection in a cellular model of myocardial reperfusion injury. Cardiovasc Res 66 (2005) 123-131
80. ATP channel and inhibition of the mPTP at reperfusion.
81. Costa A.D., Garlid K.D., West I.C., Lincoln T.M., Downey J.M., Cohen M.V., and Critz S.D. Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res 97 (2005) 329-336
82. Galkin A., and Moncada S. S-nitrosation of mitochondrial complex I depends on its structural conformation. J Biol Chem 282 (2007) 37448-37453
83. Kim J.S., Ohshima S., Pediaditakis P., and Lemasters J.J. Nitric oxide protects rat hepatocytes against reperfusion injury mediated by the mitochondrial permeability transition. Hepatology 39 (2004) 1533-1543
84. Cohen M.V., Yang X.M., and Downey J.M. Acidosis, oxygen, and interference with mitochondrial permeability transition pore formation in the early minutes of reperfusion are critical to postconditioning's success. Basic Res Cardiol 103 (2008) 464-471
85. Gomez L., Paillard M., Thibault H., Derumeaux G., and Ovize M. Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation 117 (2008) 2761-2768
86. Pagel P.S., Krolikowski J.G., Neff D.A., Weihrauch D., Bienengraeber M., Kersten J.R., and Warltier D.C. Inhibition of glycogen synthase kinase enhances isoflurane-induced protection against myocardial infarction during early reperfusion in vivo. Anesth Analg 102 (2006) 1348-1354
87. Nishino Y., Webb I.G., Davidson S.M., Ahmed A.I., Clark J.E., Jacquet S., Shah A.M., Miura T., Yellon D.M., Avkiran M., et al. Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in the mouse. Circ Res 103 (2008) 307-314
88. Muraski J.A., Rota M., Misao Y., Fransioli J., Cottage C., Gude N., Esposito G., Delucchi F., Arcarese M., Alvarez R., et al. Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med 13 (2007) 1467-1475. Comprehensive evidence highlighting PIM-1 as an Akt regulated pro-survival kinase in the heart.
89. Yamaguchi H., and Wang H.G. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 20 (2001) 7779-7786
90. Ming X.F., Viswambharan H., Barandier C., Ruffieux J., Kaibuchi K., Rusconi S., and Yang Z. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 22 (2002) 8467-8477
91. Nguyen K.T., Zong C.S., Uttamsingh S., Sachdev P., Bhanot M., Le M.T., Chan J.L., and Wang L.H. The role of phosphatidylinositol 3-kinase, rho family GTPases, and STAT3 in Ros-induced cell transformation. J Biol Chem 277 (2002) 11107-11115
92. Hamid S.A., Bower H.S., and Baxter G.F. Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Am J Physiol Heart Circ Physiol 292 (2007) H2598-2606
93. Baines C.P., Kaiser R.A., Purcell N.H., Blair N.S., Osinska H., Hambleton M.A., Brunskill E.W., Sayen M.R., Gottlieb R.A., Dorn G.W., et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434 (2005) 658-662
94. Di Lisa F., Menabo R., Canton M., Barile M., and Bernardi P. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem 276 (2001) 2571-2575
95. Nakagawa T., Shimizu S., Watanabe T., Yamaguchi O., Otsu K., Yamagata H., Inohara H., Kubo T., and Tsujimoto Y. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434 (2005) 652-658
96. Griffiths E.J., and Halestrap A.P. Protection by Cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol 25 (1993) 1461-1469
97. Griffiths E.J., and Halestrap A.P. Pyrophosphate metabolism in the perfused heart and isolated heart mitochondria and its role in regulation of mitochondrial function by calcium. Biochem J 290 Pt 2 (1993) 489-495
98. Halestrap A.P. Calcium-dependent opening of a non-specific pore in the mitochondrial inner membrane is inhibited at pH values below 7. Implications for the protective effect of low pH against chemical and hypoxic cell damage. Biochem J 278 Pt 3 (1991) 715-719
99. 2+-dependent pore of possible relevance to re-perfusion-induced injury. Evidence that ADP facilitates pore interconversion between the closed and open states. Biochem J 266 (1990) 33-39
100. 2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. Biochem J 255 (1988) 357-360
101. Duchen M.R., McGuinness O., Brown L.A., and Crompton M. On the involvement of a cyclosporin A sensitive mitochondrial pore in myocardial reperfusion injury. Cardiovasc Res 27 (1993) 1790-1794
102. Hausenloy D.J., Maddock H.L., Baxter G.F., and Yellon D.M. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?. Cardiovasc Res 55 (2002) 534-543
103. Argaud L., Gateau-Roesch O., Raisky O., Loufouat J., Robert D., and Ovize M. Postconditioning inhibits mitochondrial permeability transition. Circulation 111 (2005) 194-197
104. Lim S.Y., Davidson S.M., Hausenloy D.J., and Yellon D.M. Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore. Cardiovasc Res 75 (2007) 530-535
105. Lim S.Y., Davidson S.M., Mocanu M.M., Yellon D.M., and Smith C.C. The cardioprotective effect of necrostatin requires the cyclophilin-d component of the mitochondrial permeability transition pore. Cardiovasc Drugs Ther 21 (2007) 467-469
106. Piot C., Croisille P., Staat P., Thibault H., Rioufol G., Mewton N., Elbelghiti R., Cung T.T., Bonnefoy E., Angoulvant D., et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359 (2008) 473-481. First evidence that cyclosporin (an mPTP inhibitor) given as an adjunct to PCI limits infarct size in human myocardium. Important in terms of trial design, patient selection and establishment of proof-of-principle in humans.
107. Piper H.M., Abdallah Y., and Schafer C. The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res 61 (2004) 365-371
108. 2+ overload. Am J Physiol Heart Circ Physiol 288 (2005) H1900-1908
109. Liu X.H., Zhang Z.Y., Sun S., and Wu X.D. Ischemic postconditioning protects myocardium from ischemia/reperfusion injury through attenuating endoplasmic reticulum stress. Shock 30 (2008) 422-427
110. Ca activation in BNP protection of reperfused myocardium. J Mol Cell Cardiol 44 (2008) 717
111. +-ATPase activity in regionally ischemic rat hearts. Am J Physiol 270 (1996) H957-964
112. + exchanger confers greater cardioprotection against 90 min of myocardial ischemia than ischemic preconditioning in dogs. Circulation 100 (1999) 2519-2526 discussion 2469-2572
113. Gumina R.J., Mizumura T., Beier N., Schelling P., Schultz J.J., and Gross G.J. A new sodium/hydrogen exchange inhibitor EMD, 85131, limits infarct size in dogs when administered before or after coronary artery occlusion. J Pharmacol Exp Ther 286 (1998) 175-183
114. Cohen M.V., Yang X.M., and Downey J.M. The pH hypothesis of postconditioning: staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation 115 (2007) 1895-1903. Evidence that postconditioning prevents mPTP formation and limits injury to myocardium by maintaining intracellular acidosis during the first minutes of reperfusion.
115. Fujita M., Asanuma H., Hirata A., Wakeno M., Takahama H., Sasaki H., Kim J., Takashima S., Tsukamoto O., Minamino T., et al. Prolonged transient acidosis during early reperfusion contributes to the cardioprotective effects of postconditioning. Am J Physiol Heart Circ Physiol 292 (2007) H2004-2008
116. Inserte J., Barba I., Hernando V., Abellan A., Ruiz-Meana M., Rodriguez-Sinovas A., and Garcia-Dorado D. Effect of acidic reperfusion on prolongation of intracellular acidosis and myocardial salvage. Cardiovasc Res 77 (2008) 782-790
117. Inserte J., Barba I., Hernando V., and Garcia-Dorado D. Delayed recovery of intracellular acidosis during reperfusion prevents calpain activation and determines protection in postconditioned myocardium. Cardiovasc Res 81 (2009) 116-122
118. ATP channels, free radicals and MEK1/2. J Mol Cell Cardiol 35 (2003) 985-992
119. Gross G.J. Selective ATP-sensitive potassium channel openers: fact or fiction. J Mol Cell Cardiol 35 (2003) 1005-1007
120. ATP channels and myocardial preconditioning: an update. Am J Physiol Heart Circ Physiol 285 (2003) H921-930
121. ATP channels in preconditioning. Circ Res 87 (2000) 845-855
122. ATP channel elicits late preconditioning against myocardial infarction via protein kinase C signaling pathway. Circ Res 85 (1999) 1146-1153
123. 2+ in the rat heart as revealed by kappa-opioid receptor stimulation with U50488H. Br J Pharmacol 140 (2003) 750-758
124. ATP channel opening. Am J Physiol Heart Circ Physiol 284 (2003) H1592-1600
125. ATP channels in adult rat. Protein Pept Lett 13 (2006) 21-27
126. Yang X.M., Proctor J.B., Cui L., Krieg T., Downey J.M., and Cohen M.V. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 44 (2004) 1103-1110
127. ATP channels during reperfusion. Basic Res Cardiol 103 (2008) 472-484
128. Auchampach J.A., and Gross G.J. Reduction in myocardial infarct size by the new potassium channel opener bimakalim. J Cardiovasc Pharmacol 23 (1994) 554-561
129. Imagawa J., Baxter G.F., and Yellon D.M. Myocardial protection afforded by nicorandil and ischaemic preconditioning in a rabbit infarct model in vivo. J Cardiovasc Pharmacol 31 (1998) 74-79
130. ATP channel activation by nicorandil and 3-pyridyl pinacidil results in antiarrhythmic effect in an anesthetized rabbit model of myocardial ischemia/reperfusion. Methods Find Exp Clin Pharmacol 25 (2003) 97-110
131. Miura T., and Miki T. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol 103 (2008) 501-513